This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
by Zacks Equity Research
Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
by Zacks Equity Research
BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?
by Zacks Equity Research
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Corporation (BSX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
by Zacks Equity Research
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
by Zacks Equity Research
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.
Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Boston Scientific (BSX) reachead $86.20 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
by Zacks Equity Research
NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
by Zacks Equity Research
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
by Urmimala Biswas
The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.
CAH Stock May Gain Following the Distribution Deal With T2 Biosystems
by Zacks Equity Research
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
Integer Holdings (ITGR) Gains 30.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
by Zacks Equity Research
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
Robust Plasma Sales, New Innovations Aid Haemonetics Stock
by Zacks Equity Research
HAE's hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery
by Zacks Equity Research
AMN Healthcare aims to enhance staffing efficiency and improve operational efficiency in healthcare systems via the latest launch.
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
by Zacks Equity Research
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
TMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
by Zacks Equity Research
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks.com featured highlights include Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems
by Zacks Equity Research
Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems have been highlighted in this Screen of The Week article.
3 Profitable S&P 500 Stocks for the Best Quarter of the Year
by Tirthankar Chakraborty
Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems have been selected as the top picks with a high net income ratio.
Boston Scientific (BSX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Boston Scientific (BSX) closed at $84.54, indicating a +0.86% shift from the previous trading day.